share_log

Vivos Therapeutics | 8-K: Current report

Vivos Therapeutics | 8-K: Current report

Vivos Therapeutics | 8-K:重大事件
美股sec公告 ·  05/17 16:50
Moomoo AI 已提取核心信息
Vivos Therapeutics, Inc., a Delaware-incorporated company listed on The Nasdaq Capital Market under the trading symbol VVOS, has reported a compliance issue in a Current Report on Form 8-K filed with the SEC. The report, dated May 17, 2024, with events reported as of May 16, 2024, details the company's ongoing struggle to meet the Nasdaq Listing Rule 5550(b)(1), which requires a minimum stockholders' equity of $2.5 million. Despite previous capital raising efforts that led the company to believe it had regained compliance as of March 19, 2024, a new notice from Nasdaq on May 16, 2024, indicated that Vivos Therapeutics' stockholders' equity had fallen below the required threshold. As a result, Nasdaq has initiated delisting proceedings. The company has appealed this determination and is actively working...Show More
Vivos Therapeutics, Inc., a Delaware-incorporated company listed on The Nasdaq Capital Market under the trading symbol VVOS, has reported a compliance issue in a Current Report on Form 8-K filed with the SEC. The report, dated May 17, 2024, with events reported as of May 16, 2024, details the company's ongoing struggle to meet the Nasdaq Listing Rule 5550(b)(1), which requires a minimum stockholders' equity of $2.5 million. Despite previous capital raising efforts that led the company to believe it had regained compliance as of March 19, 2024, a new notice from Nasdaq on May 16, 2024, indicated that Vivos Therapeutics' stockholders' equity had fallen below the required threshold. As a result, Nasdaq has initiated delisting proceedings. The company has appealed this determination and is actively working to regain compliance. The appeal has stayed the delisting process, allowing Vivos Therapeutics' common stock to remain listed on Nasdaq pending the outcome of the hearing. The company acknowledges the risk of being unable to demonstrate compliance and the potential material adverse effects of delisting, including impacts on stock price, trading, capital raising, and reputation.
Vivos Therapeutics, Inc. 是一家在纳斯达克资本市场上市的特拉华州注册公司,交易代码为VVOS,该公司在向美国证券交易委员会提交的8-K表最新报告中报告了合规问题。该报告日期为2024年5月17日,报告了截至2024年5月16日的事件,详细介绍了该公司为满足纳斯达克上市规则5550(b)(1)而持续进行的努力,该规则要求最低股东权益为250万美元。尽管此前的筹资努力使该公司相信截至2024年3月19日已恢复合规,但纳斯达克于2024年5月16日发布的新通知显示,Vivos Therapeutics的股东权益已降至规定的门槛以下。因此,纳斯达克启动了退市程序。该公司已对该裁决提出上诉,并正在积极努力恢复合规。上诉暂停了退市程序,允许Vivos Therapeutics的普通股在听证会得出结果之前继续在纳斯达克上市。该公司承认无法证明合规的风险以及退市的潜在重大不利影响,包括对股价、交易、筹资和声誉的影响。
Vivos Therapeutics, Inc. 是一家在纳斯达克资本市场上市的特拉华州注册公司,交易代码为VVOS,该公司在向美国证券交易委员会提交的8-K表最新报告中报告了合规问题。该报告日期为2024年5月17日,报告了截至2024年5月16日的事件,详细介绍了该公司为满足纳斯达克上市规则5550(b)(1)而持续进行的努力,该规则要求最低股东权益为250万美元。尽管此前的筹资努力使该公司相信截至2024年3月19日已恢复合规,但纳斯达克于2024年5月16日发布的新通知显示,Vivos Therapeutics的股东权益已降至规定的门槛以下。因此,纳斯达克启动了退市程序。该公司已对该裁决提出上诉,并正在积极努力恢复合规。上诉暂停了退市程序,允许Vivos Therapeutics的普通股在听证会得出结果之前继续在纳斯达克上市。该公司承认无法证明合规的风险以及退市的潜在重大不利影响,包括对股价、交易、筹资和声誉的影响。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息